Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
News about Predictmedix AI Inc. (PMEDF) centers on its development of AI-powered health and safety technology, rapid health screening, and remote patient care platforms. Company announcements describe SmartHealth AI stations and Safe Entry Stations that use proprietary artificial intelligence and multispectral cameras to analyze physiological data patterns, predict vital parameters, and assess issues such as impairment, fatigue, and certain mental illnesses.
Recent releases highlight a multi-vertical growth strategy built around a single Core AI Engine. News items cover the launch of a Clinical-Trial AI Platform designed to simulate and optimize clinical trials, including features like adaptive simulations, patient-site optimization, cost and ROI modeling, and compliance-integrated AI. Other updates describe expansion into consumer digital health through a mobile diabetes screening platform that uses AI-driven facial and biometric analysis via smartphone for non-invasive diabetic risk scoring.
Investors and observers can also find coverage of Predictmedix AI’s capital markets activity, including non-brokered private placements, insider participation, and the stated use of proceeds to advance its AI engine, SmartHealth AI Station certification initiatives, clinical-trial applications, and B2C mobile platforms. Additional news includes participation in international investor conferences and roadshows, as well as selection for a Canadian government trade mission to Mexico to explore commercial opportunities for its health and safety technologies.
Together, these news items provide insight into how Predictmedix AI positions itself at the intersection of AI, quantum-inspired computation, and healthcare, and how it is communicating its technology roadmap, financing plans, and international engagement to the market.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced significant updates on its Safe Entry health screening technology, which identifies infectious diseases and impairments in the workplace. The Fit for Duty solution has improved its accuracy and functionality through technological advancements and clinical validations, achieving an impressive 91% accuracy in fatigue detection. The company is poised for commercial expansion in 2023, with a growing sales pipeline and plans for deployments in various industries, capitalizing on a projected $26.7 billion workplace safety market by 2027. Predictmedix aims to enhance shareholder value through partnerships and product validation.
Predictmedix (CSE:PMED, OTCQB:PMEDF) has announced the deployment of its Safe Entry solution at LongArm Engineering's Odessa, Texas facility. This implementation, secured through SBL Testing Technologies, aims to enhance workplace safety by screening staff for infectious diseases and substance use. The demand for Safe Entry is growing globally, reflecting its unique capability to detect various health issues through AI technology. The initiative underscores Predictmedix's commitment to improving health outcomes in dynamic work environments.
Predictmedix Inc. has successfully closed the final tranche of its non-brokered private placement, issuing 1,600,000 units at $0.05 each, raising $80,000. Each unit consists of a common share and half a warrant, with a two-year exercise option at $0.10 per share. The funds will support general operations and technology upgrades. Additionally, the company announced two peer-reviewed publications and significant updates to its AI algorithms, enhancing the accuracy of its Safe Entry Stations, which screen for health issues. A new independent director is being appointed following the resignation of Ajit Kumar.
Predictmedix Inc. has successfully closed the first tranche of a non-brokered private placement, issuing 8,300,000 units at a price of $0.05 per unit, totaling gross proceeds of $415,000. Each unit includes one common share and a half warrant. Proceeds will support operational costs, including technology upgrades. The company recently announced its accuracy rates for health screening solutions and is advancing towards commercialization. Safe Entry technology's peer review process is underway, expected to validate its efficacy within 90 days.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced high accuracy rates for its Fit for Work screening solutions. In a recent study involving 270 participants, the technology achieved a 98.38% accuracy in identifying respiration rate, 98.37% in core body temperature, and 85% in heart rate. Following these results, the company has commenced third-party validation for peer-reviewed publication and is advancing its intellectual property. CEO Dr. Rahul Kushwah emphasized the significance of these findings for enhancing workplace safety globally.
Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) announced a non-binding Letter of Intent (LOI) with KaTron Defence Space for the deployment of 80 Safe Entry Stations in Ankara, Turkey, with annual subscription fees projected at USD$1.4 million (CAD$1.85 million). The order is contingent upon results from an ongoing clinical study, expected to be published in a peer-reviewed journal. This technology aims to enhance workplace safety by screening for impairment and infectious disease symptoms. A formal purchase order is anticipated in the third quarter of 2022.
Predictmedix Inc. has secured a revenue-generating deployment of its Safe Entry Stations at the DeBeers Forevermark Forum 2022, taking place from June 29 - July 1, 2022. This deployment is part of an ongoing partnership with Entertainment Bay, aimed at enhancing health safety protocols at live events. The stations screen for signs of infectious diseases, including COVID-19. CEO Dr. Rahul Kushwah expressed optimism about increased interest from event organizers, indicating potential future deployments.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced its fiscal 2022 results, reporting revenues of $134,820 with a gross profit of $84,820 (63% margin), driven by the scaling of its Safe Entry Station technology. The company achieved a net loss of $1.9 million for the year, compared to a net loss of $1.6 million in 2021. Significant milestones include receiving CE Mark and ISO13485 certification, enabling commercialization in the EU, and initiating a clinical study to enhance its FDA Class II Medical Device application.
Predictmedix Inc. (CSE: PMED)(OTCQB: PMEDF) announced that Interim CEO Dr. Rahul Kushwah will present at the 12th Annual LD Micro Invitational in California on June 7, 2022. The presentation is scheduled for 11:00 a.m. Pacific time at the Four Seasons, followed by one-on-one investor meetings. Predictmedix specializes in rapid health screening solutions powered by AI, offering tools to analyze physiological data and identify health issues, including infectious diseases. For more information, visit www.Predictmedix.com.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) successfully deployed its Safe Entry Station at a major Las Vegas event, demonstrating its rapid health screening technology.
The partnership with Uptown Sports Marketing allowed the Company to showcase its AI-enabled screening solution, evaluating staff and performers for infectious diseases, including COVID-19. Dr. Rahul Kushwah noted the opportunity to engage with numerous hospitality representatives, emphasizing Las Vegas' potential as a deployment market due to its high visitor volume. The Safe Entry Station aims to enhance public health safety.